Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Brexpiprazole as Adjunctive Therapy in MDD
NCT03487198Phase 3Terminated
- Sponsor
- Otsuka Holdings
- Start
- May 2018
- Primary completion
- May 2019
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 3 trial of brexpiprazole in major depressive disorder (MDD), sponsored by Otsuka Holdings. Started May 2018; status: terminated.
02
Drugs
brexpiprazole
03
Conditions
major depressive disorder (MDD)
Beyond the preview
Go deeper on NCT03487198.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03487198.